We've created this blog to share our perspective on happenings and trends in the pharmaceutical, device, and supplement industry. We welcome your feedback.
Tuesday, December 9, 2014
What Does Risk-based Monitoring Mean for QA Auditing?
By now, we all know that risk-based monitoring isn’t just about changing the role of the CRA; it’s transforming the way clinical studies are managed. So what does that mean for QA teams who audit these new processes? Polaris president Celine Clive led a roundtable discussion about RBM and its implications for auditing at November’s North Carolina Regulatory Affairs Forum (NCRAF) meeting.
It’s a slippery subject. Traditional monitoring relied on the gold standard of on-site visits every 4-8 weeks and 100% SDV. RBM is not replacing this standard with another. RBM is a framework for customizing a monitoring approach for each study, and guess what -- “custom” is a lot trickier to audit than “standard.”